CJC-1295 extends this dramatically through a modification called the Drug Affinity Complex (DAC), which allows the peptide to bind covalently to albumin in the bloodstream
Emerging studies are exploring whether GLP-1s could also help slow the progression of kidney disease, though current findings are still preliminary
The risk appears linked to dose, formulation, cosupplements and individual susceptibility, and it can be modified by medications such as warfarin
While peptide therapy offers significant benefits, potential side effects include mild reactions like temporary fatigue, nausea, or water retention
Written by registered dietitian, Detrick Snyder, MPH, RDN